EDAP TMS Achieves Record Focal One Placements and Launches New System

EDAP TMS ( (EDAP) ) just unveiled an update.

EDAP TMS S.A. reported a record number of Focal One Robotic HIFU System placements in the first quarter of 2025, highlighting strong demand and adoption in the U.S. healthcare systems. The company also launched the new Focal One i system with enhanced features, received CE Mark designation for treating deep infiltrating endometriosis, and presented positive clinical trial results at the AUA 2025, indicating a promising outlook for its market growth and stakeholder impact.

The most recent analyst rating on (EDAP) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on EDAP TMS stock, see the EDAP Stock Forecast page.

Spark’s Take on EDAP Stock

According to Spark, TipRanks’ AI Analyst, EDAP is a Neutral.

EDAP TMS demonstrates solid revenue growth potential, particularly in its HIFU segment, supported by positive earnings call sentiment. However, issues such as negative profitability, cash flow challenges, and rising financial leverage present significant risks. The technical analysis shows upward momentum, but long-term indicators remain bearish. Valuation is unattractive due to a negative P/E ratio and absence of dividends.

To see Spark’s full report on EDAP stock, click here.

More about EDAP TMS

EDAP TMS S.A. is a global leader in robotic energy-based therapies, focusing on the development and commercialization of minimally invasive medical devices. The company specializes in High-Intensity Focused Ultrasound (HIFU) technology for the treatment of prostate cancer and other conditions, with a significant market presence in the urology sector.

Average Trading Volume: 122,866

Technical Sentiment Signal: Sell

Current Market Cap: $81.7M

For an in-depth examination of EDAP stock, go to TipRanks’ Stock Analysis page.